The R&D window during an outbreak is very short; in some cases, there is only a limited number of patients for experimental treatment.

Pharmaceutical sponsors will struggle to complete the R&D of vaccines and treatments against global health biothreats in outbreak settings until they leverage lessons learned and decisive actions to overcome practical difficulties of R&D in an outbreak setting.

In this part-2 episode, I’ll explain additional key factors that led to R&D successes during the 2014-15 Ebola virus outbreak in West Africa. If you haven’t watched the part-1 video, I’ve included the link in the description below.

Watch PART 1 Video Now

*******

Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory Affairs Specialist.

My goal is simple: Help Pharma industry leaders understand key trends, top strategies, and tools to conduct R&D in emerging markets and deliver life-changing treatments to patients faster.

*******

Do you want to deliver your clinical trial in sub-Saharan Africa safely?

Let's talk

*******

PS - Join the conversation on social!

⁠LinkedIn⁠

⁠Twitter⁠

⁠YouTube

Conducting vaccine and drug clinical trials during disease outbreaks can be a drag. Sponsors will struggle to deliver new products against global health biothreats unless they leverage lessons learned during previous studies to influence clinical research development plans during future outbreaks.

In this Episode, I will explain how lessons learned during the 2014-15 West Africa Ebola virus outbreak can supercharge R&D during future outbreaks and deliver life-saving clinical products to patients and families faster.

*******

Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory Affairs Specialist.

My goal is simple: Help Pharma industry leaders understand key trends, top strategies, and tools to conduct R&D in emerging markets and deliver life-changing treatments to patients faster.

*******

Do you want to deliver your clinical trial in sub-Saharan Africa safely?

Let's talk

******

Please like, share, and give me a 5-star; that'd be appreciated!👍🏻 👏 ❤️ ✍

PS - Join the conversation on social!⁠LinkedIn⁠

⁠Twitter⁠

⁠YouTube

Conducting R&D during disease outbreaks can be a drag. Global pharmaceutical companies will struggle to deliver new vaccines, drugs, and diagnostics against global health biothreats unless they leverage lessons learned and key success factors during previous studies to guide clinical research development plans during subsequent outbreaks.   

In this video, I will explain how lessons learned during the 2014-15 West Africa Ebola virus outbreak can supercharge R&D during future outbreaks and help deliver life-saving clinical products to patients and families faster.   

***

Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory Affairs Specialist.   

My goal is simple: Help YOU with the right tools, tips, and framework to deliver life-changing treatments to patients faster through clinical research and emerging market access.

***

PS - Join the conversation on social!

 https://www.linkedin.com/in/amosndhere 

https://twitter.com/amosndhere 

https://facebook.com/amosndhere

Regulatory authorities in Sub-Saharan Africa are scrutinizing pharmaceutical companies’ risk management and control practices with more rigor than ever before. Choosing the right insurance for human clinical trials can be difficult, especially in sub-Saharan Africa.

Clinical trial sponsors must procure appropriate insurance coverage, which must fulfill country-specific statutory requirements and provide adequate risk management and control during the life of a clinical trial.

In this episode, you will learn:

- What is clinical trial insurance? 

- Forms of insurance policies

- Types of insurance covers required

- Who should be indemnified

- Risks covered by Insurance 

- Policy limit requirements 

- Term of insurance policy

*****

Hi, I'm Dr. Amos Ndhere! I am a Medical doctor, Clinical Investigator, and Regulatory affairs specialist.

My goal is simple: Help YOU with the right tools, tips, and framework to deliver life-changing treatments to patients faster through clinical research and emerging market access.

********

Do you want to deliver your clinical trial in sub-Saharan Africa safely? 

Let's talk

********

Please like, subscribe, and leave me a comment below; that'd be appreciated!  👍🏻 👏 ❤️ ✍

PS - Join the conversation on social!

⁠LinkedIn⁠

⁠Twitter⁠

⁠YouTube

Africa's pharmaceutical market is $60B, and CAGR is about 10%. Global pharmaceutical companies will struggle to break into the growing African market until they position pharmaceutical products correctly.

In this video, I will explain how Medical Affairs can position products for the growing African market and WIN a piece of the $60B market share.

*****

Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory affairs specialist.

My goal is simple: Help YOU with the right tools, tips, and framework to deliver life-changing treatments to patients faster through clinical research and emerging market access.

******

Do you want to deliver your clinical trial in sub-Saharan Africa safely?

Let's talk

*****

Please subscribe; that'd be appreciated!👍🏻 👏 ❤️ ✍

PS - Join the conversation on social!

⁠LinkedIn⁠

⁠Twitter⁠

⁠YouTube